TAG Thoracic Endoprosthesis

COMPANY	W. L. Gore & Associates
PHONE	(800) 437-8181
WEB	www.goremedical.com

KEY FEATURES

- Soft tip improves flexibility
- Internally relines the thoracic aorta and isolates the diseased segment from blood circulation
- Comprised of an ePTFE graft with an outer self-expanding nitinol support structure

W. L. Gore & Associates (Flagstaff, AZ) recently announced that it has received FDA approval to market a modified version of its TAG thoracic endoprosthesis delivery system. The improved delivery system offers flexibility at the wire/catheter interface to facilitate tracking through challenging aortic anatomy. Additionally, the flexible, sheathless catheter delivery system facilitates passage and access through narrow and tortuous aortic anatomies. The hub component has been modified to improve ease of use and durability. Distribution of the updated delivery systems has begun, and the company plans to have this process completed across the US within the next few months.

LifeStent Vascular Stent Systems

COMPANY	Bard Peripheral Vascular
PHONE	(480) 303-2600
WEB	www.bardpv.com

KEY FEATURES

- Only commercially available stent approved for SFA and proximal popliteal interventions
- Longest vascular stent length available (170 mm)
- Sustained clinical performance

The LifeStent FlexStar and FlexStar XL Vascular Stent Systems (Bard Peripheral Vascular, Tempe, AZ) recently received FDA approval for the treatment of superficial femoral artery (SFA)/proximal popliteal lesions. Based on a multidimensional helical architecture, the LifeStent platform includes a 170-mm stent length, which is the longest commercially available vascular stent in the US.

Coupled with data from its prospective, multicenter, randomized clinical trial (RESILIENT), which demonstrated a freedom from target lesion revascularization rate of 78% versus 42% ($P < .0001$) for percutaneous transluminal angioplasty, the LifeStent Vascular Stent Systems offer physicians a device with proven clinical performance and the possibility for a one-stent treatment strategy in a select group of patients, the company says. Barry Katzen, MD, founder and medical director of Baptist Cardiac & Vascular Institute and coprincipal investigator of the RESILIENT trial, commented, "The long-term data recently presented are important because they demonstrate the sustained performance of the LifeStent vascular stent. Of particular significance to clinicians and patients is the approval of the 170-mm stent, the longest commercially available in the US."



Amphirion Deep PTA Long Balloons



COMPANY	Invatec, Inc.
PHONE	(877) 4-INVATEC
WEB	www.invatec.com

KEY FEATURES

- Available in 150-mm and tapered 210-mm long sizes
- Unique anatomically tapered design provides greater vessel conformability
- 0.018-inch crossing profile enables crossability and access
- 4-F compatible, differentiated shaft diameter design optimizes pushability and trackability
- Flexitec Ultra polymer provides anatomical conformability

Invatec's recently 510(k)-cleared Amphirion Deep (Invatec, Inc., Bethlehem, PA) line of dedicated below-the-knee percutaneous transluminal angioplasty (PTA) catheters now includes 150-mm and Tapered 210-mm Long Balloons. The Long balloons are intended to dilate stenoses in the femoral, popliteal, and infrapopliteal arteries. The unique 210-mm Long Tapered Balloon is anatomically designed to provide more precise balloon-to-vessel conformability in both diameter and length. The entire Amphirion Deep line is 4-F compatible and has a differentiated shaft diameter designed to promote flexibility and trackability without compromising the balloon's pushability. The Amphirion line has a low profile of 0.018 inch, enabling ease of crossability. According to Invatec, the Amphirion long balloon has the ability to reach, access, and treat challenging vasculature in the most distal arteries. Dr. Marco Manzi of the Abano Terme Clinic (Padova, Italy) and author of "Pedal-Plantar Loop Technique" (*Endovascular Today*, March 2009) has become an advocate for the Amphirion Deep. According to Dr. Manzi, his "technique has been largely dependent on…dedicated devices, such as the introduction of low-profile long balloon catheters giving high conformability." The Amphirion Deep 150-mm and Tapered 210-mm Long PTA Balloons are now available in the US.

GaltStick Introducer System

COMPANY	Galt Medical Corp.
PHONE	(800) 639-2800
WEB	www.galtmedical.com

KEY FEATURES

- Embedded radio-opaque marker band
- Allows for introduction of both .018- and .038-inch guidewires
- Available with or without lubricity+ hydrophilic coating
- Smooth dilator/sheath transition

The GaltStick Introducer System (Galt Medical Corporation, Garland, TX) is a 6-F coaxial sheath assembled with stiffening stylet. The GaltStick allows for the introduction of a .018-inch guidewire and .038-inch working guidewire in nonvascular procedures. The GaltStick features a smooth dilator/sheath transition and is available with or without the lubricity+ hydrophilic coating, the company stated.



Express SD Renal Monorail Premounted Stent System

COMPANY	Boston Scientific Corporation
PHONE	(888) 272-1001
WEB	www.bostonscientific.com

KEY FEATURES

- The only FDA-approved, commercially available premounted renal stent
- Additional proximal support for ostial lesions
- Tandem Architecture designed for strength, radiopacity, and flexibility
- Custom balloon lengths designed to minimize balloon overhang



Boston Scientific Corporation (Natick, MA) recently announced the US launch of its Express SD Renal Monorail Premounted Stent System. The stent was designed with unique Tandem Architecture Stent Design and additional support at the proximal end of the stent. The low-profile delivery system was designed with custom balloon lengths to minimize balloon overhang. Combined, these characteristics provide a stent engineered for excellent deliverability, accurate placement, and effective ostial support, Boston Scientific says.

The RENAISSANCE Study (single-arm, 100-patient study) demonstrated the Express SD Stent is safe and effective as an adjunct to percutaneous transluminal renal angioplasty in the treatment of certain renal artery stenosis. Nine-month primary endpoint results showed a binary restenosis rate of 21.3% (23/108), defined as the proportion of target lesions with greater than or equal to 50% diameter stenosis. The study also showed a statistically significant improvement in systolic blood pressure and no statistical difference in either diastolic blood pressure or serum creatinine levels from baseline. Secondary endpoint results included a target lesion revascularization rate of 8.1% (9/111), and a 0% (0/100) rate of stent thrombosis.

IntuiTrak Endovascular AAA System

COMPANY	Endologix, Inc.
PHONE	(800) 983-2284
WEB	www.endologix.com

KEY FEATURES

- 19-F integrated introducer to reduce sheath exchanges
- Hydrophilic coating for smooth delivery
- Precannulated 9-F contralateral access
- Simple and controlled deployment

IntuiTrak (Endologix, Inc., Irvine, CA) is an innovative system developed for the minimally invasive delivery and deployment of the Endologix Powerlink stent graft. IntuiTrak's novel design and deployment mechanism simplifies standard vascular delivery of the Powerlink device and provides exceptional accuracy and control. The low-profile delivery system features enhanced flexibility, advanced hemostasis control, and a hydrophilic coating to facilitate smooth delivery, particularly in patients with limited or difficult vascular access, the company says. Additionally, the delivery catheter has an integrated 19-F sheath, which minimizes the need to exchange introducers, thereby having the potential to minimize vessel trauma and reduce overall procedure time. ■